CY1121649T1 - Ενωσεις 6,7-διυδροπυραζολο[1,5-α]πυραζιν-4(5η)-ονης και η χρηση τους ως αρνητικοι αλλοστερικοι τροποποιητες των υποδοχεων mglu2 - Google Patents

Ενωσεις 6,7-διυδροπυραζολο[1,5-α]πυραζιν-4(5η)-ονης και η χρηση τους ως αρνητικοι αλλοστερικοι τροποποιητες των υποδοχεων mglu2

Info

Publication number
CY1121649T1
CY1121649T1 CY20191100101T CY191100101T CY1121649T1 CY 1121649 T1 CY1121649 T1 CY 1121649T1 CY 20191100101 T CY20191100101 T CY 20191100101T CY 191100101 T CY191100101 T CY 191100101T CY 1121649 T1 CY1121649 T1 CY 1121649T1
Authority
CY
Cyprus
Prior art keywords
compounds
dihydropyrazolo
pyrazine
negative allosteric
allosteric modifiers
Prior art date
Application number
CY20191100101T
Other languages
English (en)
Inventor
Sergio-Alvar Alonso-De Diego
Michiel Luc Maria Van Gool
Óscar DELGADO-GONZÁLEZ
José Ignacio Andrés-Gil
Andrés Avelino TRABANCO-SUÁREZ
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of CY1121649T1 publication Critical patent/CY1121649T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4162—1,2-Diazoles condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Η παρούσα εφεύρεση αναφέρεται σε νέα παράγωγα 6,7-διυδροπυραζολο[1,5-a]πυραζιν-4(5Η)-όνης ως αρνητικοί αλλοστερικοί τροποποιητές (NAM) του μεταβολοτροπικού υποδοχέα γλουταμινικού υποτύπου 2 («mGluR2»). Η εφεύρεση απευθύνεται, επίσης, σε φαρμακευτικές συνθέσεις που περιλαμβάνουν τέτοιες ενώσεις, σε διεργασίες για την παρασκευή τέτοιων ενώσεων και συνθέσεων και στη χρήση τέτοιων ενώσεων και συνθέσεων για την πρόληψη ή θεραπευτική αντιμετώπιση διαταραχών στις οποίες εμπλέκεται ο υπότυπος mGluR2 των μεταβολοτροπικών υποδοχέων.
CY20191100101T 2014-08-01 2019-01-24 Ενωσεις 6,7-διυδροπυραζολο[1,5-α]πυραζιν-4(5η)-ονης και η χρηση τους ως αρνητικοι αλλοστερικοι τροποποιητες των υποδοχεων mglu2 CY1121649T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP14179598 2014-08-01
PCT/EP2015/067530 WO2016016380A1 (en) 2014-08-01 2015-07-30 6,7-DIHYDROPYRAZOLO[1,5-α]PYRAZIN-4(5H)-ONE COMPOUNDS AND THEIR USE AS NEGATIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS

Publications (1)

Publication Number Publication Date
CY1121649T1 true CY1121649T1 (el) 2020-07-31

Family

ID=51257437

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20191100101T CY1121649T1 (el) 2014-08-01 2019-01-24 Ενωσεις 6,7-διυδροπυραζολο[1,5-α]πυραζιν-4(5η)-ονης και η χρηση τους ως αρνητικοι αλλοστερικοι τροποποιητες των υποδοχεων mglu2

Country Status (33)

Country Link
US (3) US10005786B2 (el)
EP (1) EP3177623B1 (el)
JP (1) JP6662846B2 (el)
KR (1) KR102531689B1 (el)
CN (1) CN106573936B (el)
AR (1) AR101392A1 (el)
AU (1) AU2015295298B2 (el)
BR (1) BR112017001726A2 (el)
CA (1) CA2954093C (el)
CL (1) CL2017000192A1 (el)
CY (1) CY1121649T1 (el)
DK (1) DK3177623T3 (el)
EA (1) EA031087B1 (el)
ES (1) ES2708215T3 (el)
HR (1) HRP20181997T1 (el)
HU (1) HUE042871T2 (el)
IL (1) IL250298A0 (el)
JO (1) JOP20150179B1 (el)
LT (1) LT3177623T (el)
MA (1) MA39582B1 (el)
ME (1) ME03320B (el)
MX (1) MX2017001452A (el)
NZ (1) NZ728122A (el)
PH (1) PH12017500161A1 (el)
PL (1) PL3177623T3 (el)
PT (1) PT3177623T (el)
RS (1) RS58279B1 (el)
SG (1) SG11201700638YA (el)
SI (1) SI3177623T1 (el)
TR (1) TR201901074T4 (el)
TW (1) TWI696624B (el)
WO (1) WO2016016380A1 (el)
ZA (1) ZA201700759B (el)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20200036063A (ko) 2014-01-21 2020-04-06 얀센 파마슈티카 엔.브이. 대사 조절형 글루탐산 작동성 수용체 제2아형의 양성 알로스테릭 조절제 또는 오르토스테릭 작동제를 포함하는 조합 및 그 용도
JP6629740B2 (ja) 2014-01-21 2020-01-15 ヤンセン ファーマシューティカ エヌ．ベー． 代謝型グルタミン酸作動性受容体サブタイプ２の正のアロステリック調節因子またはオルトステリックアゴニストを含む組み合わせ、およびそれらの使用
JOP20150179B1 (ar) * 2014-08-01 2021-08-17 Janssen Pharmaceutica Nv مركبات 6 ، 7 ثاني هيدرو بيرازولو [ 1، 5 الفا ] بيرازين – 4 (5 يد) – اون واستخدامها كمنظمات الوسترية سلبية لمستقبلات ملجور 2
JOP20150177B1 (ar) 2014-08-01 2021-08-17 Janssen Pharmaceutica Nv مركبات 6 ، 7 ثاني هيدرو بيرازولو [ 1، 5 الفا ] بيرازين – 4 (5 يد) – اون واستخدامها كمنظمات الوسترية سلبية لمستقبلات ملجور 2
CA2967153A1 (en) 2014-12-03 2016-06-09 Janssen Pharmaceutica Nv 6,7-dihydropyrazolo[1,5-.alpha.]pyrazin-4(5h)-one compounds and their use as negative allosteric modulators of mglur2 receptors
AU2015357169B2 (en) 2014-12-03 2021-03-04 Janssen Pharmaceutica Nv Radiolabelled mGluR2 PET ligands
RS60981B1 (sr) 2015-12-18 2020-11-30 Janssen Pharmaceutica Nv Radiooznačeni mglur2/3 pet ligandi
EA037941B1 (ru) 2015-12-18 2021-06-09 Янссен Фармацевтика Нв ЛИГАНДЫ mGluR2/3 ДЛЯ PET, МЕЧЕННЫЕ РАДИОАКТИВНЫМИ ИЗОТОПАМИ
JP2020011902A (ja) * 2016-10-26 2020-01-23 大日本住友製薬株式会社 縮環ピロール誘導体およびその医薬用途
CN107298682B (zh) * 2017-06-29 2019-03-01 天津药明康德新药开发有限公司 一种4,5,6,7-四氢吡唑并[1,5-a]吡嗪-2-甲酸乙酯的合成方法
CA3082976A1 (en) 2017-11-24 2019-05-31 Sumitomo Dainippon Pharma Co., Ltd. 6,7-dihydropyrazolo[1,5-a]pyrazinone derivative and medical use thereof
CA3088288A1 (en) * 2018-01-26 2019-08-01 Recordati Industria Chimica E Farmaceutica S.P.A Triazole, imidazole and pyrrole condensed piperazine derivatives and their use as modulators of mglu5 receptors

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0756200B1 (en) 1995-07-26 1999-11-10 Konica Corporation Silver halide color photographic light-sensitive material
US6482821B2 (en) 1996-12-20 2002-11-19 Hoechst Aktiengellschaft Vitronectin receptor antagonists, their preparation and their use
DE19653647A1 (de) 1996-12-20 1998-06-25 Hoechst Ag Vitronectin - Rezeptorantagonisten, deren Herstellung sowie deren Verwendung
US6754375B1 (en) 1999-07-16 2004-06-22 Packard Bioscience Company Method and system for interactively developing at least one grid pattern and computer-readable storage medium having a program for executing the method
US6831074B2 (en) 2001-03-16 2004-12-14 Pfizer Inc Pharmaceutically active compounds
US20030114448A1 (en) 2001-05-31 2003-06-19 Millennium Pharmaceuticals, Inc. Inhibitors of factor Xa
TWI372050B (en) 2003-07-03 2012-09-11 Astex Therapeutics Ltd (morpholin-4-ylmethyl-1h-benzimidazol-2-yl)-1h-pyrazoles
WO2005061507A1 (en) 2003-12-16 2005-07-07 Pfizer Products Inc. Bicyclic pyrazol-4-one cannabinoid receptor ligands and uses thereof
ES2299044T3 (es) * 2004-06-21 2008-05-16 F. Hoffmann-La Roche Ag Derivados de pirrazol-pirimidina.
WO2006030847A1 (ja) 2004-09-17 2006-03-23 Dainippon Sumitomo Pharma Co., Ltd. 新規二環性ピラゾール誘導体
DE102004054665A1 (de) 2004-11-12 2006-05-18 Bayer Cropscience Gmbh Substituierte bi- und tricyclische Pyrazol-Derivate Verfahren zur Herstellung und Verwendung als Herbizide und Pflanzenwachstumsregulatoren
KR100968291B1 (ko) 2005-02-11 2010-07-07 에프. 호프만-라 로슈 아게 Ｍｇｌｕｒ２ 길항제로서의 피라졸로-피리미딘 유도체
KR100973609B1 (ko) 2005-03-23 2010-08-03 에프. 호프만-라 로슈 아게 ｍＧｌｕＲ2 길항제로서 아세틸렌일-피라졸로-피리미딘유도체
US7998959B2 (en) 2006-01-12 2011-08-16 Incyte Corporation Modulators of 11-β hydroxyl steroid dehydrogenase type 1, pharmaceutical compositions thereof, and methods of using the same
WO2008001115A2 (en) 2006-06-29 2008-01-03 Astex Therapeutics Limited Pharmaceutical combinations of 1-cyclopropyl-3- [3- (5-m0rphoolin-4-ylmethyl-1h-benzoimidazol-2-yl) -lh-1-pyrazol- 4-yl] -urea
CN101855222A (zh) 2007-05-10 2010-10-06 通用电气健康护理有限公司 对大麻素cb2受体具有活性的咪唑并(1,2-a)吡啶和相关化合物
EP2085390A1 (en) 2008-01-31 2009-08-05 Institut National De La Sante Et De La Recherche Medicale (Inserm) Labelled analogues of halobenzamides as multimodal radiopharmaceuticals and their precursors
US9446995B2 (en) 2012-05-21 2016-09-20 Illinois Institute Of Technology Synthesis of therapeutic and diagnostic drugs centered on regioselective and stereoselective ring opening of aziridinium ions
US8222424B2 (en) 2008-03-24 2012-07-17 Novartis Ag Arylsulfonamide-based matrix metalloprotease inhibitors
WO2010024258A1 (ja) 2008-08-29 2010-03-04 塩野義製薬株式会社 Ｐｉ３ｋ阻害活性を有する縮環アゾール誘導体
MY153913A (en) 2009-05-12 2015-04-15 Janssen Pharmaceuticals Inc 7-aryl-1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors
CA2760741C (en) 2009-05-12 2018-05-01 Addex Pharma S.A. 1,2,4-triazolo [4,3-a] pyridine derivatives and their use for the treatment or prevention of neurological and psychiatric disorders
JP2013537210A (ja) 2010-09-16 2013-09-30 ノバルティス アーゲー １７α−ヒドロキシラーゼ／Ｃ１７，２０−リアーゼ阻害剤
US20130230459A1 (en) 2010-11-08 2013-09-05 Janssen Pharmaceuticals, Inc. RADIOLABELLED mGluR2 PET LIGANDS
WO2012083224A1 (en) * 2010-12-17 2012-06-21 Vanderbilt University Bicyclic triazole and pyrazole lactams as allosteric modulators of mglur5 receptors
GB201106817D0 (en) 2011-04-21 2011-06-01 Astex Therapeutics Ltd New compound
WO2012172093A1 (en) 2011-06-17 2012-12-20 Merz Pharma Gmbh & Co. Kgaa Dihydroindolizine derivate as metabotropic glutamate receptor modulators
AR088218A1 (es) 2011-07-19 2014-05-21 Infinity Pharmaceuticals Inc Compuestos heterociclicos utiles como inhibidores de pi3k
WO2013012915A1 (en) 2011-07-19 2013-01-24 Infinity Pharmaceuticals Inc. Heterocyclic compounds and uses thereof
RU2610262C2 (ru) 2011-11-03 2017-02-08 Мерк Шарп И Доум Корп. ХИНОЛИНКАРБОКСАМИДНЫЕ И ХИНОЛИНКАРБОНИТРИЛЬНЫЕ ПРОИЗВОДНЫЕ В КАЧЕСТВЕ mGLuR2-НЕГАТИВНЫХ АЛЛОСТЕРИЧЕСКИХ МОДУЛЯТОРОВ, КОМПОЗИЦИИ И ИХ ПРИМЕНЕНИЕ
JP5783264B2 (ja) 2011-11-25 2015-09-24 日本電気株式会社 セル識別子割当方法、基地局、保守サーバ、移動通信システム
US8940742B2 (en) 2012-04-10 2015-01-27 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
US20130281397A1 (en) 2012-04-19 2013-10-24 Rvx Therapeutics Inc. Treatment of diseases by epigenetic regulation
EP2666775A1 (en) 2012-05-21 2013-11-27 Domain Therapeutics Substituted pyrazoloquinazolinones and pyrroloquinazolinones as allosteric modulators of group II metabotropic glutamate receptors
JP2015520239A (ja) * 2012-06-20 2015-07-16 ヴァンダービルト ユニバーシティー Ｍｇｌｕｒ５受容体のアロステリック調節剤としての置換二環式アルコキシピラゾール類似体
US20130345204A1 (en) 2012-06-20 2013-12-26 Vanderbilt University Substituted bicyclic cycloalkyl pyrazole lactam analogs as allosteric modulators of mglur5 receptors
WO2013192350A1 (en) * 2012-06-20 2013-12-27 Vanderbilt University Substituted bicyclic aralkyl pyrazole lactam analogs as allosteric modulators of mglur5 receptors
AU2013336863A1 (en) * 2012-10-23 2015-03-19 F. Hoffmann-La Roche Ag MGlu2/3 antagonists for the treatment of autistic disorders
CN103772686B (zh) 2012-10-26 2015-01-07 苏州雷纳药物研发有限公司 一种两亲性嵌段共聚物及其制备方法、以及该共聚物与抗肿瘤药物形成的胶束载药系统
JO3368B1 (ar) 2013-06-04 2019-03-13 Janssen Pharmaceutica Nv مركبات 6، 7- ثاني هيدرو بيرازولو [5،1-a] بيرازين- 4 (5 يد)- اون واستخدامها بصفة منظمات تفارغية سلبية لمستقبلات ميجلور 2
US10017514B2 (en) 2014-08-01 2018-07-10 Janssen Pharmaceutica Nv 6,7-dihydropyrazolo[1,5-α]pyrazin-4(5H)-one compounds and their use as negative allosteric modulators of mGluR2 receptors
JO3601B1 (ar) 2014-08-01 2020-07-05 Janssen Pharmaceutica Nv مركبات 6 ، 7 ثاني هيدرو بيرازولو [ 1، 5 الفا ] بيرازين – 4 (5 يد) – اون واستخدامها كمنظمات الوسترية سلبية لمستقبلات ملجور 2
JOP20150179B1 (ar) * 2014-08-01 2021-08-17 Janssen Pharmaceutica Nv مركبات 6 ، 7 ثاني هيدرو بيرازولو [ 1، 5 الفا ] بيرازين – 4 (5 يد) – اون واستخدامها كمنظمات الوسترية سلبية لمستقبلات ملجور 2
JOP20150177B1 (ar) 2014-08-01 2021-08-17 Janssen Pharmaceutica Nv مركبات 6 ، 7 ثاني هيدرو بيرازولو [ 1، 5 الفا ] بيرازين – 4 (5 يد) – اون واستخدامها كمنظمات الوسترية سلبية لمستقبلات ملجور 2
AU2015295300B2 (en) 2014-08-01 2019-05-02 Janssen Pharmaceutica Nv 6,7-dihydropyrazolo[1,5-a]pyrazin-4(5h)-one compounds and their use as negative allosteric modulators of mGluR2 receptors
CA2967153A1 (en) 2014-12-03 2016-06-09 Janssen Pharmaceutica Nv 6,7-dihydropyrazolo[1,5-.alpha.]pyrazin-4(5h)-one compounds and their use as negative allosteric modulators of mglur2 receptors
AU2015357169B2 (en) 2014-12-03 2021-03-04 Janssen Pharmaceutica Nv Radiolabelled mGluR2 PET ligands
RS60981B1 (sr) 2015-12-18 2020-11-30 Janssen Pharmaceutica Nv Radiooznačeni mglur2/3 pet ligandi
EA037941B1 (ru) 2015-12-18 2021-06-09 Янссен Фармацевтика Нв ЛИГАНДЫ mGluR2/3 ДЛЯ PET, МЕЧЕННЫЕ РАДИОАКТИВНЫМИ ИЗОТОПАМИ

Also Published As

Publication number Publication date
US20170217972A1 (en) 2017-08-03
TWI696624B (zh) 2020-06-21
EA201692540A1 (ru) 2017-05-31
ZA201700759B (en) 2018-12-19
CA2954093A1 (en) 2016-02-04
CA2954093C (en) 2022-11-29
BR112017001726A2 (pt) 2017-11-21
US10512646B2 (en) 2019-12-24
US20200121677A1 (en) 2020-04-23
PL3177623T3 (pl) 2019-04-30
LT3177623T (lt) 2019-02-11
KR102531689B1 (ko) 2023-05-10
RS58279B1 (sr) 2019-03-29
JOP20150179B1 (ar) 2021-08-17
AU2015295298A1 (en) 2017-01-12
TW201617346A (zh) 2016-05-16
TR201901074T4 (tr) 2019-02-21
HUE042871T2 (hu) 2019-07-29
SI3177623T1 (sl) 2019-01-31
NZ728122A (en) 2022-07-29
WO2016016380A1 (en) 2016-02-04
US10005786B2 (en) 2018-06-26
EP3177623A1 (en) 2017-06-14
DK3177623T3 (en) 2019-02-25
MA39582B1 (fr) 2019-10-31
US20180256569A1 (en) 2018-09-13
MX2017001452A (es) 2017-05-09
PH12017500161A1 (en) 2017-06-28
AR101392A1 (es) 2016-12-14
EA031087B1 (ru) 2018-11-30
CN106573936B (zh) 2020-01-07
WO2016016380A8 (en) 2017-01-19
ES2708215T3 (es) 2019-04-09
JP2017522340A (ja) 2017-08-10
KR20170031247A (ko) 2017-03-20
SG11201700638YA (en) 2017-02-27
MA39582A1 (fr) 2018-06-29
AU2015295298B2 (en) 2019-07-11
JP6662846B2 (ja) 2020-03-11
CN106573936A (zh) 2017-04-19
ME03320B (me) 2019-10-20
IL250298A0 (en) 2017-03-30
CL2017000192A1 (es) 2017-07-28
HRP20181997T1 (hr) 2019-01-25
EP3177623B1 (en) 2018-11-07
PT3177623T (pt) 2019-02-01

Similar Documents

Publication Publication Date Title
CY1121649T1 (el) Ενωσεις 6,7-διυδροπυραζολο[1,5-α]πυραζιν-4(5η)-ονης και η χρηση τους ως αρνητικοι αλλοστερικοι τροποποιητες των υποδοχεων mglu2
CY1119499T1 (el) Ενωσεις 6,7-διυδροπυραζολο[1,5-α]πυραζιν-4(5η)-ονης και η χρηση τους ως αρνητικοι αλλοστερικοι τροποποιητες των υποδοχεων mglur2
CY1121123T1 (el) Ενωσεις 6,7-διυδροπυραζολο[1,5-α]πυραζιν-4(5η)-ονης και η χρηση τους ως αρνητικοι αλλοστερικοι τροποποιητες των υποδοχεων mglu2
NZ768368A (en) Modulators of cystic fibrosis transmembrane conductance regulator
CY1123059T1 (el) Αναστολη του διαυλου ιοντων παροδικου δυναμικου του υποδοχεα α1
EA202091115A1 (ru) Производные хиназолина, применяемые для лечения вич
AR101403A1 (es) (4s)-4-(4-ciano-2-metoxifenilo)-5-etoxi-2,8-dimetilo-1,4-dihidro-1,6-naftiridin-3-carboxamida, su purificación para su uso como principio activo farmacéutico, un procedimiento para su preparación y su empleo en el tratamiento de enfermedades cardiovasculares
EA201692496A1 (ru) 6,7-ДИГИДРОПИРАЗОЛО[1,5-a]ПИРАЗИН-4(5H)-ОНОВЫЕ СОЕДИНЕНИЯ И ИХ ПРИМЕНЕНИЕ В КАЧЕСТВЕ ОТРИЦАТЕЛЬНЫХ АЛЛОСТЕРИЧЕСКИХ МОДУЛЯТОРОВ РЕЦЕПТОРОВ MGLUR2
EA201790949A1 (ru) Замещенные 2,4-диаминохинолины в качестве новых противораковых средств
EA201792057A1 (ru) Конденсированные бициклические гетероарильные производные с активностью ингибиторов пролилгидроксилазы
CY1120602T1 (el) [1,2,4]τριαζολο[4,3-β]πυριδαζινες για χρηση στη θεραπευτικη αντιμετωπιση πολλαπλασιαστικων ασθενειων
CY1119449T1 (el) Ενωσεις 1,2,4-τριαζολο|4,3-α]πυριδινης και η χρηση αυτων ως θετικων αλλοστερiκων ρυθμιστων των υποδοχεων mglur2
CR20160373A (es) Ciclopentanos, tetrahidrofuranos y pirrolidinas sustituidas como antagonistas del receptor de orexina
EA201301135A1 (ru) Трициклические производные n,n'-замещенных 3,7-диазабицикло[3.3.1]нонанов и лекарственные средства на их основе
EA201790020A1 (ru) Соединения, фармацевтические композиции и их применение при лечении нейродегенеративных заболеваний
EA201790795A1 (ru) СОЕДИНЕНИЯ 4Н-ПИРИДО[1,2-a]ПИРИМИДИН-4-ОНА
UA96476U (uk) ЗАСТОСУВАННЯ 7-(3-ГІДРОКСИФЕНІЛ)-6-КАРБЕТОКСИ-5-МЕТИЛ-4,7-ДИГІДРО[1,2,4]ТРИАЗОЛО-[1,5-a]ПІРИМІДИНУ ДЛЯ КОРЕКЦІЇ ПОРУШЕНЬ СТРУКТУРИ КІСТКОВОЇ ТКАНИНИ ПРИ ГІПОТИРЕОЇДНИХ СТАНАХ